Outcomes
The primary outcome was the proportion of participants who seroconverted by 28 days after vaccination for the fractional dose compared with the standard dose in the per-protocol population. Seroconversion was defined as a four-fold or greater increase in neutralising antibody titre between pre-vaccination and post-vaccination samples as measured by PRNT